AstraZeneca rejoins leading US drug lobby group
AstraZeneca has rejoined the Pharmaceutical Research and Manufacturers of America (PhRMA), the main U.S. drug lobby group, nearly two years after parting ways with it.
The British pharmaceutical company’s return follows last year’s announcement of a $3.5 billion investment in the United States to boost research, development, and manufacturing capabilities by end of 2026.
The company returns to the trade body amid preparations by pharmaceutical companies to address potential tariffs and drug import duties under the administration of President Donald Trump, as per reported by Reuters.
"We are also expanding our presence in the United States with significant investments in research, development and manufacturing," said Pascal Soriot, AstraZeneca’s Chief Executive Officer.
Soriot added AstraZeneca is "committed to working with PhRMA and policymakers to ensure the U.S. remains the global leader in biomedical innovation and that medicines are affordable for everyone who needs them."
In May 2023, the London-listed company had decided to leave the group and explore alternative advocacy approaches at both state and federal levels.
Next Story